What TB-500 is - and where it comes from
TB-500 is a synthetic 43-amino-acid peptide derived from Thymosin Beta-4 (TB4), a naturally occurring protein found in high concentrations in blood platelets, wound fluid, and many tissues. The full TB4 protein is 43 amino acids long; TB-500 essentially replicates that sequence with specific attention to the central LKKTET motif, which researchers have identified as functionally critical for actin binding and cellular migration.
Thymosin Beta-4 was first isolated by Allan Goldstein's laboratory at George Washington University in the early 1980s and later linked to wound-healing signaling. The synthetic fragment TB-500 was developed to study that specific mechanism in isolation, particularly in equine veterinary models where soft-tissue injuries are common and economically significant.
TB-500's biological logic is elegant: it sequesters free G-actin, preventing premature polymerization at the wound edge and allowing cells to migrate into damaged areas with greater efficiency.
Mechanism, in plain English
Actin is the structural protein that cells use to move. When tissue is damaged, cells near the wound need to migrate into the gap to begin repair. TB-500's LKKTET sequence binds free G-actin (the monomeric, unpolymerized form), modulating the ratio of free to filamentous actin. This shift is associated with more efficient cell migration in preclinical assays.
Beyond actin dynamics, the preclinical literature also identifies downstream effects on angiogenesis (new blood vessel formation), inflammatory cytokine modulation, and extracellular matrix remodeling via collagen synthesis pathways.
Want all 31 muscle recovery compounds in one place?
The Peptexa Muscle Recovery & Healing guide covers TB-500, BPC-157, and every compound in this category - mechanism, evidence level, and FDA status for each.
What the preclinical evidence shows
The strongest published evidence for TB-500 comes from wound-healing and soft-tissue repair models in rodents and horses. Key findings in the literature include accelerated tendon repair in rat Achilles transection models, improved cardiac function after induced myocardial infarction in mice, and enhanced corneal healing in rabbit models. The cardiac and neural injury data is particularly notable because it suggests potential systemic signaling beyond the local wound environment.
Equine veterinary research has explored TB-500 in tendon and ligament injuries due to the prevalence and economic cost of these conditions in performance horses. Some of this data informed early human interest in the compound, even though veterinary research does not directly translate to human clinical outcomes.
The most-cited foundational reviews include Goldstein (2000) in Annals of the New York Academy of Sciences and Huff et al. (2012) in International Immunopharmacology. No large, randomized, placebo-controlled human trial has been published as of this review date.
The animal evidence is broad and consistently positive, but the jump from rodent and horse models to human clinical outcomes is where the scientific community appropriately pauses.
FDA status
TB-500 is not FDA-approved for any human indication. On July 23-24, 2026, the FDA Pharmacy Compounding Advisory Committee reviewed TB-500 alongside several other peptides and voted to recommend a rule-making review of compounding access. Any change to compounding access would require a separate formal rule-making step and would still not constitute FDA approval of TB-500 as a drug. Last reviewed 2026-08-09.
TB-500 is also listed as a prohibited substance by WADA for in-competition use in athletes subject to anti-doping regulations.
Common synonyms researchers use
TB-500 · TB500 · Thymosin Beta-4 fragment · TB4 fragment · LKKTET peptide · Tβ4 (44-47)
Safety & adverse-event landscape
In preclinical studies, TB-500 has been administered to rodents and horses without reported significant adverse events at doses used in experimental protocols. The compound's role in angiogenesis has prompted theoretical discussion about whether it could promote growth in existing neoplastic tissue - this is a hypothetical concern that has not been formally studied and should be discussed with a qualified oncologist before any consideration of use.
Human adverse-event data is limited to anecdotal reports and has not been systematically studied. Peptexa does not provide dosing guidance, sourcing recommendations, or protocol advice. Always consult a qualified healthcare provider before any decision involving peptides or experimental compounds.
Frequently asked questions
Want this in your inbox weekly?
Get the Peptexa Top-5 free - five compounds, mechanism-led. One email a week. No spam.
The full Muscle Recovery & Healing reference
31 compounds. Mechanism, evidence level, and FDA status for every one. Get the complete guide now.
Get the Muscle Recovery & Healing Guide →